Iovance Biotherapeutics Reports Q3 Revenue Growth of 80% and EPS Beat
Iovance Biotherapeutics (IOVA) reported third-quarter financial results that exceeded analyst expectations for both earnings per share and revenue. The company posted a GAAP EPS of -$0.05, outperforming estimates by $0.04, while total revenue reached $121.47 million, surpassing projections by $5.9 million. The significant revenue growth was driven by product sales, which totaled approximately $122 million. This represents an 80.1% increase compared to the same period last year and a notable rise from previous quarters, signaling strong commercial momentum for the company's therapeutic offerings.
Tickers: $IOVA